Blackmores Limited (ASX: BKL) set to partner with the leaders in the research and cultivation of medicinal cannabis in order to attract commercial agreements to manufacture and sell cannabis-related products that could be popular with consumers.
The vitamins and supplements company plans to “seek authorisation to launch medical cannabis products through general practitioners and medical specialists” via its fast-growing Bioceuticals alternative and herbal therapies healthcare business.
For medicinal cannabis the vitamins maker has pinpointed the areas of palliative care, brain tumours and chronic pain as areas for clinical trials in an attempt to show the benefits of medical cannabis products.
Read the full article on fool.com.au
What do you think about Blackmores Limited potential foray in the medical cannabis sector?
As Australia’s most trusted vitamin and supplement brand since 2009 and with an impressive catalogue of vitamins, minerals, and nutritional supplements, a global footprint and a market capitalisation of more than $1.6 billion it makes sense for the leading natural health company in the country to be investigating the opportunities in the medical marijuana industry.
Blackmores’ distribution capabilities alone, allow for the possibility to be Australia’s market leader in the medical cannabis industry, a move that could prove pivotal to sustain the long-term growth shareholders in the ASX listed company have come to expect.
Stay tuned for an update on Blackmores medical marijuana moves, which could very well see THC infused capsules placed on a shelf alongside fish oil and vitamin c tablets one day in the future.
This information on this site is for general information purposes only. It is not intended as financial or investment advice.